Aoife is currently Chief Medical Officer at Synlogic, a privately held biopharmaceutical company focused on developing synthetic biotics to treat rare metabolic disorders. She joined Synlogic in September 2016. Previously she was Vice President and Head of the Rare Disease Innovation Unit at Biogen where she was responsible for research and development of the Biogen rare disease portfolio which included programs ranging from pre-clinical to commercial. She spent 6 years at Biogen in roles of increasing responsibility where her contributions included leading the late-phase development for nusinersen in spinal muscular atrophy as well as the late-phase development and world-wide regulatory approval of ALPROLIX and ELOCTATE, treatments for Hemophilia B and Hemophilia A. During her tenure at Biogen she led a number of external collaborations including those with Sangamo Biosciences, SOBI and AGTC. She also helped to establish the gene therapy collaboration with UPenn.
Prior to joining Biogen, Aoife was Director of Clinical Development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 Diabetes. Aoife holds a medical degree from Trinity College Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.